Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.17 USD | -3.97% | -8.94% | +2.29% |
May. 13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
May. 10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.29% | 1.56B | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer